Immune memory shapes human polyclonal antibody responses to H2N2 vaccination

Autor: Yuhe R. Yang, Julianna Han, Hailee R. Perrett, Sara T. Richey, Alesandra J. Rodriguez, Abigail M. Jackson, Rebecca A. Gillespie, Sarah O’Connell, Julie E. Raab, Lauren Y. Cominsky, Ankita Chopde, Masaru Kanekiyo, Katherine V. Houser, Grace L. Chen, Adrian B. McDermott, Sarah F. Andrews, Andrew B. Ward

Publikováno v: Cell Reports, Vol 43, Iss 5, Pp 114171- (2024)

Summary: Influenza A virus subtype H2N2, which caused the 1957 influenza pandemic, remains a global threat. A recent phase 1 clinical trial investigating a ferritin nanoparticle vaccine displaying H2 hemagglutinin (HA) in H2-naive and H2-exposed adul

Externí odkaz: https://doaj.org/article/a0c95ce71b2948fb906573474156e723

Epitope-Specific Serological Assays for RSV: Conformation Matters

Autor: Emily Phung, Lauren A. Chang, Kaitlyn M. Morabito, Masaru Kanekiyo, Man Chen, Deepika Nair, Azad Kumar, Grace L. Chen, Julie E. Ledgerwood, Barney S. Graham, Tracy J. Ruckwardt

Publikováno v: Vaccines, Vol 7, Iss 1, p 23 (2019)

Respiratory syncytial virus (RSV) causes substantial morbidity and mortality in children and older adults. An effective vaccine must elicit neutralizing antibodies targeting the RSV fusion (F) protein, which exists in two major conformations, pre-fus

Externí odkaz: https://doaj.org/article/f0f63836d3ed411b93eda73d51fa2a8a

Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial.

Autor: Cristina Carter, Katherine V Houser, Galina V Yamshchikov, Abbie R Bellamy, Jeanine May, Mary E Enama, Uzma Sarwar, Brenda Larkin, Robert T Bailer, Richard Koup, Grace L Chen, Shital M Patel, Patricia Winokur, Robert Belshe, Cornelia L Dekker, Barney S Graham, Julie E Ledgerwood, VRC 703 study team

Publikováno v: PLoS ONE, Vol 14, Iss 9, p e0222178 (2019)

BackgroundSeasonal influenza results in significant morbidity and mortality worldwide, but the currently licensed inactivated vaccines generally have low vaccine efficacies and could be improved. In this phase 1 clinical trial, we compared seasonal i

Externí odkaz: https://doaj.org/article/773f84c8b2754fefbbb0e4d8279bce2c

A prefusion-stabilized RSV F subunit vaccine elicits B cell responses with greater breadth and potency than a postfusion F vaccine

Autor: Lauren A. Chang, Emily Phung, Michelle C. Crank, Kaitlyn M. Morabito, Tonya Villafana, Filip Dubovsky, Judith Falloon, Mark T. Esser, Bob C. Lin, Grace L. Chen, Barney S. Graham, Tracy J. Ruckwardt

Publikováno v: Science translational medicine. 14(676)

There is currently no licensed vaccine for respiratory syncytial virus (RSV). Here, we assess the effect of RSV fusion protein (F) conformation on B cell responses in a post hoc comparison of samples from the DS-Cav1 [prefusion (pre-F)] and MEDI7510

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b812c6e5ca970c86f994ae6e96897819
https://pubmed.ncbi.nlm.nih.gov/36542692

Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial

Autor: Peifeng Chen, Anita Arthur, Kaitlyn M. Morabito, Kristin Leach, Xiaolin Wang, Grace L. Chen, Attila Nagy, Lauren A. Chang, Jon Cooper, Amy L. Chamberlain, Janel Holland-Linn, Olga Vasilenko, Alicia T. Widge, Shufeng Bai, Judith A Stein, LaSonji A. Holman, Cristina Carter, Iris Pittman, Deepika Gollapudi, Lisa A. Kueltzo, Colleen Fridley, Michelle C. Crank, Amritha Menon, William Whalen, Mridul Ghosh, Cynthia S. Hendel, Martha Nason, Amy Liu, Althaf Hussain, Laura Novik, Pernell Williams, Maria Burgos Florez, Robert T. Bailer, Thuy Nguyen, Brenda Larkin, Tracy J. Ruckwardt, Pamela Costner, Lam Le, Zhong Zhao, Elizabeth Carey, Vera Ivleva, Jennifer Walters, John R. Mascola, Jennifer Cunningham, Olga Trofymenko, Ya-chen Chang, Somia P. Hickman, Martin R. Gaudinski, Richard M. Schwartz, Slobodanka D. Manceva, Kevin Carlton, Barney S. Graham, Rahul Ragunathan, Jason G. D. Gall, Ana M. Ortega-Villa, Colin Tran, Sarah H. Plummer, Abidemi Ola, Ro Shauna S Rothwell, Ingelise J. Gordon, Mingzhong Chen, Jamie G. Saunders, Aba Mensima Eshun, Bob C. Lin, Azad Kumar, Nina M. Berkowitz, Xun Liu, Cora Trelles Cartagena, Emily Phung, Galina Yamshchikov, Joe Horwitz, Sarah O’Connell, Florence Kaltovich, Floreliz Mendoza, LaShawn Requilman, Man Chen, Preeti Apte, Christopher Lee, Renunda Hicks

Publikováno v: Lancet Respir Med

Multiple active vaccination approaches have proven ineffective in reducing the substantial morbidity and mortality caused by respiratory syncytial virus (RSV) in infants and older adults (aged ≥65 years). A vaccine conferring a substantial and sust

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81ae60b574c97c5be6e3eabd0b1e70f3
https://doi.org/10.1016/s2213-2600(21)00098-9